Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 91–100, page 10 of 20. Filter these by subject, year and score in the research library →

1. Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/comparing-clinical-effect-sizes-of-souvenaidtm-lecanemab-and-41428477

   … daily living (IADLs) for lecanemab, donanemab, and Souvenaid™, based on published pivotal clinical trial data.MethodsCohen's d on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) was computed using standardized mean differences …

2. Early Outcomes of Lecanemab for Alzheimer's Disease in the Veterans Health AdministrationResearch summary

   Research summaries · alzhub.org/study/early-outcomes-of-lecanemab-for-alzheimer-s-disease-in-the-veterans-41375579

   … dwelling) initiated lecanemab. Seventeen patients (53%) had mild cognitive impairment, 15 (47%) had mild dementia; mean baseline MoCA score was 21.3 (SD 3.4). At 7 months following treatment initiation, we assessed process, …

3. Eligibility for lecanemab and donanemab in Korea under Appropriate Use RecommendationsResearch summary

   Research summaries · alzhub.org/study/eligibility-for-lecanemab-and-donanemab-in-korea-under-appropriate-41225766

   … 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample). Applying MMSE z-scores increased eligibility to 38.4% and 33.7%, respectively. Over a third of participants were excluded due to …

4. Lecanemab for Alzheimer's Disease: Effectiveness and Value — Final Evidence ReportResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-alzheimer-s-disease-effectiveness-and-value-final-40d8b15f

   An independent US drug-pricing watchdog analyzed how lecanemab's actual price compares to its clinical benefit. It concluded the drug would need to cost roughly $8,900 to $21,500 per year to be considered good value for money by …

5. Lecanemab over a two-year duration: Key insights from a regional specialty medical centerResearch summary

   Research summaries · alzhub.org/study/lecanemab-over-a-two-year-duration-key-insights-from-a-regional-41581261

   … events associated with lecanemab. Results A total of 109 (58.3 %) patients were diagnosed with MCI, and 78 (41.7 %) had mild dementia prior to starting lecanemab. The presence of baseline microbleeds was associated with a higher …

6. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-a-second-in-class-therapy-for-the-management-of-early-38779110

   … traditional approval of lecanemab for the treatment of Alzheimer's disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets Aβ soluble …

7. Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting systemResearch summary

   Research summaries · alzhub.org/study/real-world-safety-profile-of-lecanemab-a-disproportionality-analysis-cbaaba6e

   Background Lecanemab, an antiamyloid monoclonal antibody, has emerged as a treatment option for Alzheimer disease. However, there is a pressing need for real-world evidence to inform clinical practice, particularly regarding its …

8. Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer’s disease: Evidence from a multidimensional real-world studyResearch summary

   Research summaries · alzhub.org/study/safety-and-effectiveness-of-lecanemab-in-chinese-patients-with-early-41069006

   … compared to baseline. Lecanemab demonstrated a favorable safety profile in Chinese patients with early AD. Cognitive stability and biomarker changes over 6 months suggest potential efficacy, though high dropout rates and absence …

9. Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging AbnormalitiesResearch summary

   Research summaries · alzhub.org/study/amyloid-pet-changes-during-lecanemab-treatment-in-patients-with-and-42912549

   Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable …

10. Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting systemResearch summary

    Research summaries · alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157

    … drug events (ADEs) of lecanemab and aducanumab separately, there is a lack of comparison between these two drugs, and no exploration of gender differences. This study aims to compare the adverse reaction signals of lecanemab and …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.